Cost-Effectiveness Analysis of Fixed-Dose Tiotropium/Olodaterol versus Tiotropium for COPD Patients in China

References

• Chronic Obstructive Pulmonary Disease Group. Respiratory Diseases Branch of Chinese Medical Association Chronic Obstructive Pulmonary Disease Working Committee of the Respiratory Physician Branch of the Chinese Medical Doctor Association, Guidelines for the diagnosis and treatment of chronic obstructive pulmonary disease. Chin J Tuberc Respir Dis. 2021;44(3):170–204.
   Google Scholar
• Wang C, Xu J, Yang L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross‐sectional study. Lancet. 2018;391(10131):1706–1717. doi:10.1016/S0140-6736(18)30841-9
   PubMed Web of Science ®Google Scholar
• Li M, Wang F, Chen R, et al. Factors contributing to hospitalization costs for patients with COPD in China: a retrospective analysis of medical record data. Int J Chron Obstruct Pulmon Dis. 2018;13:3349–3357. doi:10.2147/COPD.S175143
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease (GOLD), Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease; 2021. Available from: https://goldcopd.org/2022-gold-reports-2/. Accessed December 21, 2021.
   Google Scholar
• Horita N, Goto A, Shibata Y, et al. Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev. 2017;2(2):CD012066. doi:10.1002/14651858.CD012066.pub2
   PubMed Web of Science ®Google Scholar
• Maqsood U, Ho TN, Palmer K, et al. Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2019;3(3):CD012930. doi:10.1002/14651858.CD012930.pub2
   PubMedGoogle Scholar
• Rodrigo GJ, Price D, Anzueto A, et al. LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis. 2017;12:907–922. doi:10.2147/COPD.S130482
   PubMed Web of Science ®Google Scholar
• Blair HA. Tiotropium/Olodaterol: a Review in COPD. Drugs. 2019;79(9):997–1008. doi:10.1007/s40265-019-01133-w
   PubMed Web of Science ®Google Scholar
• Buhl R, Maltais F, Abrahams R, et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4). Eur Respir J. 2015;45(4):969–979. doi:10.1183/09031936.00136014
   PubMed Web of Science ®Google Scholar
• Singh D, Ferguson GT, Bolitschek J, et al. Tiotropium plus olodaterol shows clinically meaningful improvements in quality of life. Respir Med. 2015;109(10):1312–1319. doi:10.1016/j.rmed.2015.08.002
   PubMed Web of Science ®Google Scholar
• Beeh KM, Westerman J, Kirsten AM, et al. The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2015;32:53–59. doi:10.1016/j.pupt.2015.04.002
   PubMed Web of Science ®Google Scholar
• Beeh KM, Derom E, Echave-Sustaeta J, et al. The lung function profile of once-daily tiotropium and olodaterol via Respimat® is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler® (ENERGITO® study). Int J Chron Obstruct Pulmon Dis. 2016;11(1):193–205. doi:10.2147/COPD.S95055
   PubMedGoogle Scholar
• Calverley PMA, Anzueto AR, Carter K, et al. Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomized, parallel-group, active-controlled trial. Lancet Respir Med. 2018;6(5):337–344. doi:10.1016/S2213-2600(18)30102-4
   PubMed Web of Science ®Google Scholar
• Lee HW, Park J, Jang EJ, et al. Comparisons of exacerbations and mortality among LAMA/LABA combinations in stable chronic obstructive pulmonary disease: systematic review and Bayesian network meta-analysis. Respir Res. 2020;21(1):310. doi:10.1186/s12931-020-01540-8
   PubMed Web of Science ®Google Scholar
• Schlueter M, Gonzalez-Rojas N, Baldwin M, et al. Comparative efficacy of fixed-dose combinations of long-acting muscarinic antagonists and long-acting beta2-agonists: a systematic review and network meta-analysis. Ther Adv Respir Dis. 2016;10(2):89–104. doi:10.1177/1753465815624612
   PubMed Web of Science ®Google Scholar
• Rogliani P, Matera MG, Ritondo BL, et al. Efficacy and cardiovascular safety profile of dual bronchodilation therapy in chronic obstructive pulmonary disease: a bidimensional comparative analysis across fixed-dose combinations. Pulm Pharmacol Ther. 2019;2019:101841. doi:10.1016/j.pupt.2019.101841
   Google Scholar
• Liu GG, Hu SL, Wu JH. China Guidelines for Pharmacoeconomic Evaluations. 2020th ed. Beijing: China Market Press; 2020.
   Google Scholar
• National Bureau of Statistics. Average life expectancy of population; 2015. Available from: http://www.stats.gov.cn/. Accessed October 12, 2021.
   Google Scholar
• Bai CX, Tang Y, Xin JB, et al. The efficacy and safety of tiotropium/olodaterol fixed-dose combination in patients with chronic obstructive pulmonary disease: a pooled subgroup analysis of Tonado 1+2. Chin J Tuberc Respir Dis. 2019;42(11):838–844.
   Google Scholar
• Wedzicha JA, Buhl R, Singh D, et al. Tiotropium/Olodaterol Decreases Exacerbation Rates Compared with Tiotropium in a Range of Patients with COPD: pooled Analysis of the Tonado /DYNAGITO Trials. Adv Ther. 2020;37(10):4266–4279. doi:10.1007/s12325-020-01438-3
   PubMed Web of Science ®Google Scholar
• Ferguson GT, Fležar M, Korn S, et al. Efficacy of Tiotropium + Olodaterol in Patients with Chronic Obstructive Pulmonary Disease by Initial Disease Severity and Treatment Intensity: a Post Hoc Analysis. Adv Ther. 2015;32(6):523–536. doi:10.1007/s12325-015-0218-0
   PubMed Web of Science ®Google Scholar
• Wilson MR, Patel JG, Coleman A, et al. Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic model. Int J Chron Obstruct Pulmon Dis. 2017;12:997–1008. doi:10.2147/COPD.S124420
   PubMed Web of Science ®Google Scholar
• Spencer M, Briggs AH, Grossman RF, et al. Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics. 2005;23(6):619–637. doi:10.2165/00019053-200523060-00008
   PubMed Web of Science ®Google Scholar
• Wise RA, Anzueto A, Cotton D, et al. Tiotropium Respimat inhaler and the risk of death in COPD. N Engl J Med. 2013;369(16):1491–1501. doi:10.1056/NEJMoa1303342
   PubMed Web of Science ®Google Scholar
• Selya-Hammer C, Gonzalez-Rojas Guix N, Baldwin M, et al. Development of an enhanced health-economic model and cost-effectiveness analysis of tiotropium + olodaterol Respimat fixed-dose combination for chronic obstructive pulmonary disease patients in Italy. Ther Adv Respir Dis. 2016;10(5):391–401. doi:10.1177/1753465816657272
   PubMed Web of Science ®Google Scholar
• Starkie HJ, Briggs AH, Chambers MG, et al. Predicting EQ-5D Values Using the SGRQ. Value Health. 2011;14(2):354–360. doi:10.1016/j.jval.2010.09.011
   PubMed Web of Science ®Google Scholar
• Zhou X, Wang Z, Song Y, et al. Periodontal health and quality of life in patients with chronic obstructive pulmonary disease. Respir Med. 2011;105(1):67–73. doi:10.1016/j.rmed.2010.06.017
   PubMed Web of Science ®Google Scholar
• Rutten-van Mölken MP, Hoogendoorn M. Holistic preferences for 1-year health profiles describing fluctuations in health: the case of chronic obstructive pulmonary disease. Pharmacoeconomics. 2009;27(6):465–477. doi:10.2165/00019053-200927060-00003
   PubMed Web of Science ®Google Scholar
• Sichuan Provincial Medical Security Bureau. Sichuan Provincial Centralized Procurement and Price Supervision Platform for Medicines and Instruments; 2023. Available from: https://www.scyxzbcg.cn/std/login.html. Accessed March, 31 2023.
   Google Scholar
• Liu J, He X, Wu J. Economic Evaluation of Triple Therapy with Budesonide/Glycopyrrolate/ Formoterol Fumarate for the Treatment of Moderate to Very Severe Chronic Obstructive Pulmonary Disease in China Using a Semi-Markov Model. Appl Health Econ Health Policy. 2022;20(5):743–755. doi:10.1007/s40258-022-00732-1
   PubMed Web of Science ®Google Scholar
• Chen X, Wang N, Chen Y, et al. Costs of chronic obstructive pulmonary disease in urban areas of China: a cross-sectional study in four cities. Int J Chron Obstruct Pulmon Dis. 2016;11:2625–2632. doi:10.2147/COPD.S118523
   PubMed Web of Science ®Google Scholar
• Cai D, Shi S, Jiang S, et al. Estimation of the cost-effective threshold of a quality-adjusted life year in China based on the value of statistical life. Eur J Health Econ. 2022;23(4):607–615. doi:10.1007/s10198-021-01384-z
   PubMed Web of Science ®Google Scholar
• Capel M, Mareque M, Álvarez CJ, et al. Cost-Effectiveness of Fixed-Dose Combinations Therapies for Chronic Obstructive Pulmonary Disease Treatment. Clin Drug Investig. 2018;38(7):611–620. doi:10.1007/s40261-018-0646-0
   PubMed Web of Science ®Google Scholar
• Tebboth A, Ternouth A, N G-R. UK-specific cost-effectiveness of tiotropium + olodaterol fixed-dose combination versus other LAMA + LABA combinations in patients with COPD. Clinicoecon Outcomes Res. 2016;8:667–674. doi:10.2147/CEOR.S116546
   PubMedGoogle Scholar
• van Boven J, Kocks J, Postma MJ. Cost-effectiveness and budget impact of the fixed-dose dual bronchodilator combination tiotropium–olodaterol for patients with COPD in the Netherlands. Int J Chron Obstruct Pulmon Dis. 2016;11:2191–2201. doi:10.2147/COPD.S114738
   PubMed Web of Science ®Google Scholar
• Selya-Hammer C, Gonzalez-Rojas Guix N, Baldwin M, et al. Development of an enhanced health-economic model and cost-effectiveness analysis of tiotropium + olodaterol Respimat fixed-dose combination for chronic obstructive pulmonary disease patients in Italy. Ther Adv Respir Dis. 2016;10:391–401.
   PubMed Web of Science ®Google Scholar
• Chen R, Gao Y, Wang H, et al. Association Between Adherence to Maintenance Medication in Patients with COPD and Acute Exacerbation Occurrence and Cost in China: a Retrospective Cohort Database Study. Int J Chron Obstruct Pulmon Dis. 2020;15:963–971. doi:10.2147/COPD.S234349
   PubMed Web of Science ®Google Scholar
• Wang ML, Avashia BH. Interpreting periodic lung function tests in individuals: the relationship between 1- to 5-year and long-term FEV1 changes. Chest. 2006;130(2):493–499. doi:10.1016/S0012-3692(15)51866-7
   PubMed Web of Science ®Google Scholar
• Scanlon PD, Connett JE, Waller LA, et al. Smoking Cessation and Lung Function in Mild-toModerate Chronic Obstructive Pulmonary Disease. The Lung Health Study. Am J Respir Crit Care Med. 2000;161(2Pt1):381–390. doi:10.1164/ajrccm.161.2.9901044
   PubMedGoogle Scholar